Nirav N Shah, MD | Medical College of Wisconsin

Nirav N. Shah, MD

Assistant Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English, Gujarati

Secondary Appointments

Hematology
Internal Medicine
Medical Oncology

Contact Information

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Nirav Shah, MD, MSHP, is Assistant Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in lymphoma, CAR-T cell therapy, and stem cell transplant at Froedtert Hospital. He graduated with honors and Alpha Omega Alpha Honor Society membership from the University of Illinois at Chicago College of Medicine in 2008. He then completed his Internal Medicine residency at Massachusetts General Hospital in Boston, Massachusetts in 2011. Post-residency, he took a position at Northwestern Memorial Hospital in Hospitalist medicine before proceeding to the University of Pennsylvania where he completed both hematology/oncology fellowship and a Master’s degree in Health Policy research in 2015.

Research Interests

Dr. Shah's current clinical and research interests include developing new cell based and immune therapies for patients with non-Hodgkin and Hodgkin lymphoma. He is specifically involved in the development of new CAR-T cell therapies for blood cancers. His professional memberships include the American Society of Hematology and the American Society of Clinical Oncology.

Dr. Shah is board certified by the American Board of Internal Medicine (ABIM) in Hematology, Medical Oncology, and Internal Medicine.

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.

(Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL.) J Clin Oncol. 2020 Feb 10;38(5):415-422 PMID: 31815579 SCOPUS ID: 2-s2.0-85079075868 12/10/2019
Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT.

(Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Saini N, Shah AR, Patel RD, Ahmed S, Shah NN, Cashen AF, Hamadani M, Fenske TS.) Blood Adv. 2020 Jan 14;4(1):47-54 PMID: 31899797 PMCID: PMC6960457 SCOPUS ID: 2-s2.0-85078133666 01/04/2020
Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

(Chen YB, Shah NN, Renteria AS, Cutler C, Jansson J, Akbari M, Chen C, Quadri S, Parfionovas A, Devine SM.) Blood Adv. 2019 Dec 10;3(23):4136-4146 PMID: 31821456 PMCID: PMC6963235 12/11/2019
Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis.

(Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M.) Blood Cancer J. 2019 12 03;9(12):97 PMID: 31796726 PMCID: PMC6890709 SCOPUS ID: 2-s2.0-85075936084 12/05/2019
Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis.

(Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, Shaw BE, D'Souza A.) Amyloid. 2019 Dec;26(4):210-215 PMID: 31347424 SCOPUS ID: 2-s2.0-85074118154 07/28/2019
Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease.

(Chhabra S, Jerkins JH, Conto JE, Zellner K, Shah NN, Hari PN, Hamadani M.) Leuk Lymphoma. 2019 Nov 25:1-6 PMID: 31762357 SCOPUS ID: 2-s2.0-85075533403 11/26/2019
Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database.

(Guru Murthy GS, Szabo A, Hamadani M, Fenske TS, Shah NN.) Oncologist. 2019 Nov;24(11):1488-1495 PMID: 31467178 PMCID: PMC6853108 SCOPUS ID: 2-s2.0-85071466837 08/31/2019
Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.

(Solomon SR, St Martin A, Shah NN, Fatobene G, Al Malki MM, Ballen KK, Bashey A, Bejanyan N, Bolaños Meade J, Brunstein CG, DeFilipp Z, Champlin RE, Fuchs EJ, Hamadani M, Hematti P, Kanakry CG, McGuirk JP, McNiece IK, Ciurea SO, Pasquini MC, Rocha V, Romee R, Patel SS, Vasu S, Waller EK, Wingard JR, Zhang MJ, Eapen M.) Blood Adv. 2019 Oct 08;3(19):2836-2844 PMID: 31582392 PMCID: PMC6784523 SCOPUS ID: 2-s2.0-85073446898 10/05/2019
Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma.

(Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P.) Blood Cancer J. 2019 07 29;9(8):56 PMID: 31358733 PMCID: PMC6663939 SCOPUS ID: 2-s2.0-85069933026 07/31/2019
Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals.

(Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M.) JAMA Netw Open. 2019 Jul 03;2(7):e196476 PMID: 31276175 SCOPUS ID: 2-s2.0-85068511187 07/06/2019
Gut microbiome and CAR-T therapy.

(Abid MB, Shah NN, Maatman TC, Hari PN.) Exp Hematol Oncol. 2019;8:31 PMID: 31827982 PMCID: PMC6862813 12/13/2019
Gut microbiome and CAR-T therapy

(Abid MB, Shah NN, Maatman TC, Hari PN.) Experimental Hematology and Oncology. 19 November 2019;8(1) SCOPUS ID: 2-s2.0-85075584597 11/19/2019